Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 2, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. Group 2: Allegations Against Molina Healthcare - The lawsuit alleges that Molina failed to disclose several material adverse facts, including issues related to medical cost trend assumptions and a dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant cut in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina regarding its business and operations were materially misleading and lacked a reasonable basis [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 15, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - The class period for the MoonLake Immunotherapeutics securities class action is from March 10, 2024, to September 29, 2025 [1]. - Investors who purchased common stock during this period may be eligible for compensation without any upfront fees through a contingency fee arrangement [2]. - To participate in the class action, investors must apply by December 15, 2025, to serve as lead plaintiff, representing other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant settlements for investors [4]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, MoonLake Immunotherapeutics made false or misleading statements regarding the efficacy of its product SLK compared to traditional monoclonal antibodies, specifically BIMZELX [5]. - Key points of contention include claims about the molecular targets and clinical benefits of SLK, which were allegedly overstated, leading to investor damages when the truth was revealed [5].

Core Viewpoint - CarMax, Inc. experienced a significant decline in share price following the announcement of CEO Bill Nash's termination and a negative Q3 2026 sales outlook, indicating deeper issues within the company [1][7]. Financial Performance - CarMax reported a 24% year-over-year decline in net EPS for Q2 2026, with retail used unit sales down 5.4% and comparable store used unit sales down 6.3% [5]. - The CarMax Auto Finance (CAF) loan portfolio faced challenges, with revenue declining by 11.02% year-over-year due to a $142 million loan loss provision, marking a nearly 40% sequential increase and a 24% year-over-year jump [6]. Management and Corporate Governance - The termination of CEO Bill Nash on November 6, 2025, raised concerns about the company's leadership and strategic direction [1][7]. - Prior to the CEO's termination, CarMax had assured investors of strong growth prospects, claiming a fragmented market would support continued sales and earnings growth [4]. Legal and Regulatory Issues - Hagens Berman, a national shareholders rights firm, is investigating potential legal claims against CarMax related to misleading disclosures about its business model and growth prospects [2][3]. - The class action litigation focuses on whether CarMax intentionally misled investors regarding its financial health and the quality of its CAF portfolio [7].

Core Viewpoint - A class action lawsuit has been filed against StubHub Holdings, Inc. by Kirby McInerney LLP on behalf of investors who acquired StubHub securities during its September 2025 IPO, alleging that the company failed to disclose significant financial issues that misled investors [1][2]. Summary by Sections Lawsuit Details - The lawsuit claims that StubHub did not disclose changes in payment timing to vendors, which adversely affected free cash flow, leading to materially misleading financial reports and IPO offering documents [2]. - Investors who suffered losses have until January 23, 2026, to request lead plaintiff appointment [2]. Financial Impact - StubHub reported a negative free cash flow of $4.6 million for Q3 2025, a 143% decrease from the previous year's positive free cash flow of $10.6 million [3]. - Following this earnings report, StubHub's stock price dropped by $3.95, or approximately 21.0%, from $18.82 to $14.87 per share [3]. - By November 24, 2025, StubHub's stock price fell to $12.01, nearly 50% below its IPO price of $23.50 per share [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Cepton, Inc. to secure legal counsel before the December 8, 2025 deadline for a securities class action related to the company's misleading statements during the Class Period from July 29, 2024, to January 6, 2025 [1][5]. Group 1: Legal Action Details - Investors who purchased or sold Cepton common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 8, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has consistently ranked in the top 4 for securities class action settlements since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations, including failing to disclose a credible third-party bid that valued Cepton at more than double the Koito Acquisition [5]. - It is claimed that the Board of Directors did not adequately explore this offer and failed to disclose its terms, depriving shareholders of the opportunity to make an informed decision regarding the Koito Acquisition [5].

Core Viewpoint - A class action lawsuit has been filed against StubHub Holdings, Inc. for allegedly misleading investors regarding its IPO registration statement, particularly concerning free cash flow and vendor payment timing changes [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that StubHub's registration statement was materially false and misleading, omitting critical information about changes in vendor payment timing and its adverse effects on free cash flow [2]. - StubHub reported a free cash flow of negative $4.6 million for Q3 2025, a 143% decrease from the positive $10.6 million reported in the same quarter the previous year [3]. - The company's net cash provided by operating activities fell to $3.8 million, a 69.3% decrease from $12.4 million in the prior year [3]. Group 2: Stock Performance - Following the release of disappointing financial results, StubHub's stock price dropped by $3.95 per share, or 20.9%, closing at $14.87 on November 14, 2025 [4]. - By the time the class action commenced, StubHub's stock had declined nearly 56% from its IPO price of $23.50, trading as low as $10.31 per share [4].

New York, New York--(Newsfile Corp. - November 25, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of Jayud Global Logistics Ltd. during the specified Class Period, highlighting potential compensation opportunities for affected investors [2][3]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between April 21, 2023, and April 30, 2025, and investors must act by January 20, 2026, to serve as lead plaintiff [2][4]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. Group 2: Allegations Against Jayud - The lawsuit alleges that Jayud made materially false and misleading statements, failed to disclose involvement in a fraudulent stock promotion scheme, and omitted critical information regarding stock price manipulation [6]. - Specific allegations include the use of offshore accounts for coordinated share dumping and misleading public statements about the company's business and operations [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [5].

New York, New York--(Newsfile Corp. - November 24, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Nidec Corporation (OTC: NJDCY) resulting from allegations that Nidec Corporation may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Nidec Corporation securities you may be entitled to compensation without payment of any out of pocket fees or costs thr ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Agilon Health, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance and Stock Impact - On August 4, 2025, Agilon Health reported its second quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [3]. - Following this announcement, Agilon Health's stock experienced a significant decline of 51.5% on August 5, 2025 [3]. Group 2: Legal Actions and Investor Rights - Shareholders who purchased Agilon Health securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the alleged misleading information [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].